Table 1. Baseline characteristics of the population in each study arm.
| Audit-based education | Guidelines and prompts | Usual practice | All practices total | Statistical test | |
|---|---|---|---|---|---|
| List sizes for trial practices | NPar χ2 | ||||
| Trial population | |||||
| Patients | 272,467 (39.4%) | 223,730 (32.4%) | 195,307 (28.24%) | 691,504 (100%) | P<0.001 |
| Mean list size | 9082 | 6992 | 6300 | 7436 | |
| Adult population | |||||
| Patients | 223,847 (39.6%) | 181,318 (32.1%) | 159,851 (28.29%) | 565,016 (100%) | P<0.001 |
| Mean list size | 7462 | 5666 | 5156 | 6075 | |
| Demographics of population | |||||
| Age (years) | |||||
| n | 272,467 (39.4%) | 223,730 (32.4%) | 195,307 (28.24%) | 691,504 (100%) | ANOVA |
| Mean | 41.4 | 40.1 | 41.8 | 41.1 | P<0.001 |
| s.d. | 22.3 | 22.2 | 22.6 | 22.4 | |
| Gender | |||||
| Female | 135,305 (49.7%) | 110,600 (49.4%) | 98,457 (50.4%) | 344,362 (49.8%) | Pearson χ2 |
| Male | 137,162 (50.3%) | 113,130 (50.6%) | 96,850 (49.6%) | 347,142 (50.2%) | P<0.001 |
| Multiple deprivation index score | |||||
| n | 250,832 (38.9%) | 208,577 (32.3%) | 185,651 (28.8%) | 645,060 (100%) | ANOVA |
| Mean | 16.1 | 20.5 | 15.6 | 17.4 | P<0.001 |
| s.d. | 13.1 | 14.7 | 12.6 | 13.7 | |
| Ethnicity for population | Pearson χ2 | ||||
| Not recorded or not stated | 155,035 (56.9%) | 96,946 (43.3%) | 104,723 (53.6%) | 356,704 (51.6%) | P<0.001 |
| White | 75,249 (27.6%) | 82,851 (37.0%) | 71,547 (36.6%) | 229,647 (33.2%) | |
| Mixed | 2607 (1.0%) | 3737 (1.7%) | 1483 (0.8%) | 7827 (1.1%) | |
| Asian or Asian British | 25,088 (9.2%) | 26,925 (12.0%) | 8289 (4.2%) | 60,302 (8.7%) | |
| Black or black British | 11,875 (4.4%) | 10,306(4.6%) | 6857 (3.5%) | 29,038 (4.2%) | |
| Chinese or other ethnicity | 2613 (1.0%) | 2965 (1.3%) | 2408 (1.2%) | 7986 (1.2%) | |
| Trial practices (n) | 272,467 (100.0%) | 223,730 (100.0%) | 195,307 (100.0%) | 691,504 (100.0%) | |
| Comorbidities | Pearson χ2 | ||||
| Diabetes | 10,969 (4.9%) | 9465 (5.2) | 7322 (4.6) | 27,756 (4.9) | P<0.001 |
| Hypertension | 35,513 (15.9) | 27,216 (15.0) | 25,680 (16.1) | 88,409 (15.6) | P<0.001 |
| Heart failure | 1659 (0.7) | 1581 (0.9) | 1313 (0.8) | 4553 (0.8) | P<0.001 |
| Peripheral vascular disease | 1341 (0.6) | 1342 (0.7) | 1147 (0.7) | 3830 (0.7) | P<0.001 |
| Ischemic heart disease | 8491 (3.8) | 6654 (3.7) | 6266 (3.9) | 21,411 (3.8) | P<0.001 |
| Cerebrovascular disease | 2472 (1.1) | 2302 (1.3) | 1994 (1.2) | 6768 (1.2) | P<0.001 |
Abbreviation: ANOVA, analysis of variance.
Complete case analysis including deaths and leavers during the trial.Bold values indicate the total of the three columns to the left.